Achilles Therapeutics plc (ACHL) Misses Q3 EPS by 7c

Achilles Therapeutics plc (NASDAQ: ACHL) reported Q3 EPS of ($0.48), $0.07 worse than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Achilles Therapeutics plc (ACHL) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Nexgen Energy sharing technical information with BHP as Nexgen looks to raise over $ 1 billion for Rook I mine - Reuters
• Increasing unusual call volume: INDA LODE XIFR FRSH JMKE SYK BRUN MUU NRG LEN VIAV PAR ALM